Tate & Lyle plc (TATE) ORD GBP0.2916666667
2.50p
(0.39%)
- Add to watchlist
- Create an alert
- This stock can be held in a
2.50p
(0.39%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
2.50p
(0.39%)
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
HL comment (21 February 2024)
This was driven by softer consumer demand and order timing, combined with the group’s decision to pass on lower costs customers.
The renewal of customer contracts for the 2024 calendar year is expected to deliver a return to volume growth in the fourth-quarter.
Revenue guidance has been marginally lowered, now expected "slightly lower" than the prior year. There was no change to cash profit (EBITDA) expectations, for growth of 7-9%.
The shares were down 1% in early trading.
Our view
Third-quarter results were a slight disappointment for Tate & Lyle, who create ingredients like sweeteners and fibres to improve the nutritional value of food and drinks. The company’s continued to see reduced demand for some end products and persistent de-stocking by customers. That’s led them to forecast year end revenues to be slightly lower than last year. We’re continuing to monitor the potential impact from new weight loss drugs, though we remain sceptical about whether these will move the dial.
On a positive note, the Group's making good on its promise to streamline operations and focus on the most profitable parts of the business. The margin benefits are coming through, and an underlying cash profit (EBITDA) margin of 20.8% over the first half was a step up from last year, which itself saw an improvement.
The core business is in food & beverage solutions, with smaller units focusing on European sweeteners and the sugar alternative Sucralose. But it's in the core business, specifically solution-based partnerships, that we see as a key growth driver. This is where it partners with customers to create bespoke solutions to their dietary and nutritional needs. Deeper relationships and closer ties add an element of stickiness to the business, and enable Tate & Lyle to leverage its technical expertise.
Acquisitions and expansions are a key part of this plan, and we've seen a ramp-up in internal and external investment. Cash flows are also strong enough to support some well-timed debt repurchases, bringing down interest costs, which is helping to support the margin expansion. The balance sheet is strong enough without these actions, but it's refreshing to see some prudent capital allocation supporting longer-term goals.
The sale of Primary Products last year, now in the form of a joint venture called Primient, was part of the solutions led revamp. Retaining a large stake means Tate still has interests in North and Latina America, where it operates. Last year was tricky, with performance hurt by operational challenges and higher costs. But demand looks robust, and a successful round of price hikes means the outlook is promising. This'll be a key driver of cash flow as dividends from Primient get passed on to Tate.
The renewed focus on speciality ingredients and solutions, strong management team and a balance sheet with enough firepower to expand all give scope for optimism. The valuation, roughly 11 times expected earnings, isn't too demanding and has come down over the quarter. In the short term, volume challenges and the potential impacts from new weight loss drugs continue to loom heavy overhead. It'll take some knockout performances for sentiment to shift.
Tate & Lyle key facts
Forward price/earnings ratio (next 12 months): 10.5
Ten year average forward price/earnings ratio: 11.3
Prospective dividend yield (next 12 months): 3.4%
Ten year average prospective dividend yield: 4.6%
All ratios are sourced from Refinitiv, based on previous day’s closing values. Please remember yields are variable and not a reliable indicator of future income. Keep in mind key figures shouldn’t be looked at on their own – it’s important to understand the big picture.
Important information - This article isn’t personal advice. If you’re not sure whether an investment is right for you please seek advice. If you choose to invest the value of your investment will rise and fall, so you could get back less than you put in.
This article is not advice or a recommendation to buy, sell or hold any investment. No view is given on the present or future value or price of any investment, and investors should form their own view on any proposed investment. This article has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is considered a marketing communication. Non-independent research is not subject to FCA rules prohibiting dealing ahead of research, however HL has put controls in place (including dealing restrictions, physical and information barriers) to manage potential conflicts of interest presented by such dealing. Please see our full non-independent research disclosure for more information.
Previous Tate & Lyle plc updates
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.